$SINT

Sintx Technologies, Inc.

SINTX Technologies develops, manufactures and commercializes silicon nitride biomaterials, composites, devices and related technologies for medical and other high-value applications. Its biomedical products include spinal implants and the SiNAPTIC® Foot & Ankle Osteotomy Wedge System, and it develops materials for other implant uses. SINTX also produces antipathogenic silicon nitride powders and components for potential use in products such as masks, filters and wound care devices. Its silicon nitride is made in forms including solid and porous ceramics, powder, polymer composites and coatings. SINTX makes and sells silicon nitride products and components, including spinal fusion devices manufactured for CTL Amedica, and produces ceramic parts for electrical, aerospace and other industrial customers. It also develops products for third-party manufacturers and medical-device partners. Its manufacturing facilities and corporate headquarters are in Salt Lake City, Utah, and its products are primarily sold in the United States.

1
1
0

No SEC Form 4 filings for $SINT in the last 30 days.

See all $SINT insider activity →
Low

SINTX secures patents in Europe, Canada, Japan and South Korea

SINTX Technologies (NASDAQ:SINT) announced two patent issuances and three allowances in Europe, Canada, Japan, and South Korea for its silicon nitride technologies. The patents cover coatings, manufacturing processes, and materials for medical and industrial uses. The company aims to expand commercially, leveraging its IP portfolio and recent facility upgrades. According to the CEO, robust IP protection is critical for this expansion.

SINTX Technologies, Inc. (SINT) Targets Initial Implant Availability in 2027

SINTX Technologies completed its additive manufacturing facility and aims for FDA 510(k) clearance for custom extremity implants. Initial availability is targeted for Q1 2027, pending regulatory and manufacturing milestones. Broader distribution depends on further clearances and validation.

SINTX Technologies Inc (SINT) (Q3 2026) Earnings Call Highlights: Record Revenue Surge

SINTX Technologies reported Q3 2026 revenue growth with a 62% gross margin, up from 45% in Q3 2025. The company executed a warrant call, generating $2 million. Q4 2026 revenue guidance is uncertain due to delivery timing. Commercialization of the Synergy foot and ankle system has begun, and the company is developing a 3D-printed silicon nitride PEEK biocomposite platform. Cash reserves were $2 million as of September 30, 2026, with $5 million remaining under its at-the-market offering.

SINT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SINT (Sintx Technologies, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent SINT coverage spans earnings, financial news and corporate actions.

What's driving SINT

AlphAI scores every news story that mentions SINT with an AI model for sentiment and relevance, and aggregates insider trades from Sintx Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SINT

Score

SINTX secures patents in Europe, Canada, Japan and South Korea

SINTX Technologies (NASDAQ:SINT) announced two patent issuances and three allowances in Europe, Canada, Japan, and South Korea for its silicon nitride technologies. The patents cover coatings, manufacturing processes, and materials for medical and industrial uses. The company aims to expand commercially, leveraging its IP portfolio and recent facility upgrades. According to the CEO, robust IP protection is critical for this expansion.

SINTX Technologies Inc (SINT) (Q3 2026) Earnings Call Highlights: Record Revenue Surge

SINTX Technologies reported Q3 2026 revenue growth with a 62% gross margin, up from 45% in Q3 2025. The company executed a warrant call, generating $2 million. Q4 2026 revenue guidance is uncertain due to delivery timing. Commercialization of the Synergy foot and ankle system has begun, and the company is developing a 3D-printed silicon nitride PEEK biocomposite platform. Cash reserves were $2 million as of September 30, 2026, with $5 million remaining under its at-the-market offering.

$SINTMedEarnings

SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon

An FDA-cleared implant for foot and ankle surgery is now being sold by SINTX

SINTX Technologies reported a 10x increase in third-quarter revenue year-over-year, with reduced operating losses. The company launched its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System and is exploring additional healthcare applications for its silicon nitride technology. SINTX also regained compliance with Nasdaq's equity requirement and raised approximately $5.5M in gross proceeds.

$SINTMedOffering· $2.01M · closed

SINTX Technologies, Inc. delivered call notices to holders of its outstanding Class B Common Stock Purchase Warrants pursuant to the call provisions…

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 1, 2026, SINTX Technologies, Inc. (the “Company”) delivered call notices to holders of its outstanding Class B Common Stock Purchase Warrants pursuant to the call provisions described in the Company’s Current Report on Form 8-K furnished that d

Related tickers